Relapsed/Refractory Non-Hodgkin's Lymphoma

Oncology·MeSH: Lymphoma, Non-Hodgkin

Prevalence

30.0 / 100K

1 drug in development·1 company·1 clinical trial

Drug Pipeline by Phase

Phase 1(1)
DrugCompany
[14C]ABT-199AbbVie Inc. (ABBV)

Frequently asked questions

How many drugs are in development for Relapsed/Refractory Non-Hodgkin's Lymphoma?

BioSniper tracks 1 drug in development for Relapsed/Refractory Non-Hodgkin's Lymphoma across 1 company.

How many clinical trials target Relapsed/Refractory Non-Hodgkin's Lymphoma?

There are 1 clinical trial targeting Relapsed/Refractory Non-Hodgkin's Lymphoma tracked by BioSniper.

What is the prevalence of Relapsed/Refractory Non-Hodgkin's Lymphoma?

The estimated prevalence of Relapsed/Refractory Non-Hodgkin's Lymphoma is approximately 30.0 per 100,000 population.

Deep-dive into Relapsed/Refractory Non-Hodgkin's Lymphoma

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Relapsed/Refractory Non-Hodgkin's Lymphoma — Drugs in Development & Clinical Trials | BioSniper